Chemical synapses are the predominant neuron-to-neuron contact in the central nervous system. Presynaptic boutons of neurons contain hundreds of vesicles filled with neurotransmitters, the diffusible signaling chemicals. Changes in the number of synapses are associated with numerous brain disorders, including Alzheimer's disease and epilepsy. However, all current approaches for measuring synaptic density in humans require brain tissue from autopsy or surgical resection. We report the use of the synaptic vesicle glycoprotein 2A (SV2A) radioligand [ 11 C]UCB-J combined with positron emission tomography (PET) to quantify synaptic density in the living human brain. Validation studies in a baboon confirmed that SV2A is an alternative synaptic density marker to synaptophysin. First-in-human PET studies demonstrated that [ 11 C]UCB-J had excellent imaging properties. Finally, we confirmed that PET imaging of SV2A was sensitive to synaptic loss in patients with temporal lobe epilepsy. Thus, [ 11 C]UCB-J PET imaging is a promising approach for in vivo quantification of synaptic density with several potential applications in diagnosis and therapeutic monitoring of neurological and psychiatric disorders.
INTRODUCTION
The human brain is estimated to contain 100 trillion synapses (1) . Structural disruption or loss of synapses can result in network dysfunction with aberrant neuronal signaling. Synaptic pathology has been associated with many brain disorders. Reduced synaptic density in the seizure onset zone in patients with epilepsy has been shown in neuropathological studies (2) (3) (4) (5) , and synapse loss in the hippocampus and cerebral cortex has been closely associated with cognitive impairment in Alzheimer's disease (6) (7) (8) (9) . Moreover, regional synaptic changes have been demonstrated in patients with autism (10), depression (11) , or schizophrenia (12, 13) . However, all approaches for synapse quantification in humans depend on examination of brain tissue from autopsy or surgical resection, thereby greatly limiting the utility of this approach for early diagnosis and therapeutic monitoring. A minimally invasive method for quantification of synaptic density in the living human brain is therefore desired.
Quantification of synaptic density in brain tissue is typically performed using immunohistochemistry or electron microscopy. Antibodies targeting key proteins located in the pre-or postsynaptic neurons, such as synaptophysin (SYN), which is present in the membrane of synaptic vesicles (14) , are commonly used for immunohistochemical detection of synaptic elements. In vivo quantification of proteins in the living brain is possible using positron emission tomography (PET), and the use of PET imaging is well established for a wide range of brain receptors, transporters, and enzymes, as well as other proteins (15) . In vivo quantification of synapses throughout the entire brain may be possible using PET when combined with a synapse-specific radioligand, but to date, no radioligands have been reported that bind to a protein ubiquitously present on synaptic vessels. To this end, we developed [ 11 
C]UCB-J [(R)-1-((3-(
11 C-methyl-11 C)pyridin-4-yl)methyl)-4-(3,4,5-trifluorophenyl)pyrrolidin-2-one] as a best-in-class PET radioligand for imaging of the synaptic vesicle glycoprotein 2A (SV2A) and demonstrated its potential in nonhuman primates (16) .
SV2 is present in all vertebrates and is an integral membrane protein located similarly to SYN in the presynaptic vesicle membranes. SV2 consists of three isoforms, with SV2A as the only isoform ubiquitously and homogeneously located in synapses across the brain (17) . Thus, PET imaging and quantification of SV2A signal may be an excellent in vivo proxy of synaptic density. Other SV2A radioligands have been reported recently, including [ UCB-A binding could be quantified in rats and pigs (19) . [ 18 F]UCB-H displayed good kinetics in rats (20) and nonhuman primates (21) , and acceptable dosimetry in humans (22) , but a human brain imaging study has not yet been reported.
Here, we demonstrate that [ 11 C]UCB-J binds to SV2A and serves as a synaptic density marker in nonhuman primates as well as in people, in a first-in-human imaging study in healthy controls and in patients with epilepsy. In healthy humans, we characterized the pharmacokinetic and imaging properties of [ 11 C]UCB-J and confirmed SV2A-specific binding. We also demonstrated proof of concept in epilepsy patients that changes in synaptic density can be monitored noninvasively. 
RESULTS
SV2A is a marker of synaptic density-A baboon case study To validate [ 11 C]UCB-J as a marker of synaptic density, we performed a PET measurement in an olive baboon (Papio anubis), after which the animal was sacrificed and the brain was dissected for postmortem tissue studies. After injection of [ Tissues were sampled from 12 regions in the baboon's brain and analyzed by Western blotting and SV2A homogenate binding assays. To determine whether SV2A can, like the gold standard SYN, be used as a marker of synaptic density, we compared regional densities of SV2A and SYN using selective antibodies for SV2A, SYN, and the housekeeping protein b-actin. SV2A and SYN signals were strong and specific in all gray matter regions but absent or weak in the centrum semiovale (Fig. 1C) . The in vitro regional distribution of SV2A [optical density (OD)] correlated well with in vivo PET-measured [ 11 C]UCB-J V T (Fig.  1D ). There was an excellent linear correlation between SV2A and the "gold standard" synaptic marker SYN across all gray matter regions analyzed (Fig. 1E ), indicating that SV2A can be used as an alternative to SYN for accurate synapse quantification.
To further evaluate the relationship between in vivo [ 11 C]UCB-J binding and SV2A density, homogenate binding studies were performed to determine affinity (K d ) and regional SV2A densities (B max ). Saturation studies using [ ]UCB-J bound with an average K d of 3.9 ± 0.6 nM (±SD, n = 11) to a homogeneous population of binding sites, as illustrated in the temporal cortex, the region with the highest SV2A density (Fig. 1, F and G) ; 11 other regions of the brain are shown in figs. S1 and S2. The regional SV2A B max ranged from 2.2 pmol/mg protein (111 pmol/ml brain tissue) in the pons to 19.9 pmol/mg protein (918 pmol/ml brain tissue) in the temporal cortex; specific binding could not be reliably detected in the centrum semiovale. The in vitro B max values also correlated well with the in vivo V T values measured in baboon (Fig. 1H ). There was excellent correlation between the in vitro B max derived from homogenate binding and the regional SV2A Western blot measurements (Fig. 1I) .
To evaluate the cellular distribution of SV2A, we compared the localization of SV2A and SYN using selective antibodies. Immunoreactivity was evaluated in a section of the somatosensory cortex and the adjacent white matter using confocal microscopy ( Fig. 1 , J and K). There was considerable overlap between the staining for SYN and SV2A. SV2A and SYN staining was negligible in the white matter but high in the gray matter (Fig. 1J ). SV2A and SYN staining was absent in neuronal cell bodies (white arrows in Fig. 1K ) but high at the border of a proximal dendrite (yellow arrow in Fig. 1K ). These data further support SV2A as an alternative to SYN for synapse quantification.
[ 11 C]UCB-J is a promising radioligand in humans Five healthy subjects (37 ± 13 years of age; four males and one female) were evaluated with PET after an intravenous bolus injection of [ (table S2) .
PET summation images in representative subject 1 demonstrated high radioactivity concentrations in all gray matter regions and low uptake in white matter regions ( Fig. 2A ; all other subjects, fig. S3 ) similar to the baboon. [ 11 C]UCB-J had peak SUV of 7 to 11 across gray matter brain regions at 10 to 25 min after injection, and the centrum semiovale showed considerably lower uptake than all examined gray matter regions in subject 1 ( Fig. 2B ; all other subjects, fig. S4 ). For all subjects, [ 11 C]UCB-J displayed favorable kinetics in all gray matter regions, with a steady decline in regional radioactivity over time, starting~20 min after injection.
Kinetic analysis provided measures of both SV2A binding (V T and BP ND ) and blood flow (K 1 ). Regional V T values were estimated using the 1T model, which provided suitable fits for the TACs and reliable estimates of the V T values (Fig. 2B ). V T values ranged from 5.2 ± 0.5 ml/cm 3 in the centrum semiovale to 22.5 ± 2.0 ml/cm 3 in the putamen (Fig. 2C  and table S3 ). The coefficient of variation for V T was 9 ± 3% across the examined brain regions, indicating a low intersubject variability. The K 1 values, determined from the 1T model and reflecting blood flow and tracer extraction, were heterogeneous across brain regions and ranged from 0.123 ± 0.017 ml/cm 3 per minute in the centrum semiovale to 0.376 ± 0.048 ml/cm 3 per minute in the putamen ( Fig. 2D and table S4 ). Regional binding potential (BP ND ) values equal the ratio of specific to nondisplaceable (free plus nonspecific) binding and were determined from the V T values ( Fig. 2C and table S3 ) as V T,region /V T,centrum_semiovale − 1. BP ND values ranged from 1.69 ± 0.29 in the hippocampus to 3.33 ± 0.37 in the putamen (Fig. 2E  and table S5 ). The intersubject coefficient of variation for BP ND was 12 ± 2%.
To confirm that [
11 C]UCB-J binds specifically to SV2A, displacement studies were performed with the SV2A-selective anticonvulsant levetiracetam (23) . Three additional healthy subjects (32 ± 9 years of age; one male and two females) underwent a bolus plus constant infusion scan with [ 11 C]UCB-J under baseline conditions. One of these subjects (30 years of age; female) and two additional healthy subjects (35 and 46 years of age; two males) underwent a displacement measurement in which 1500-mg levetiracetam was administered intravenously 60 to 65 min after the start of [ fig. S5B ) and in PET images (subject 8 in Fig. 3C; all subjects, fig. S6 ). In the displacement study, mean V T for the 90-to 120-min periods was 44% lower in gray matter regions and 12% lower in the centrum semiovale, when compared to mean V T for the 90-to 120-min period measured under baseline conditions. UCB-J binding was evaluated with PET in three patients with temporal lobe epilepsy (TLE) and mesial temporal sclerosis (52 ± 6 years of age; three males). BP ND maps were generated with the simplified reference tissue model 2 (24) using the centrum semiovale as a reference brain region for nondisplaceable binding. In all three patients, the unilateral decrease in uptake in the hippocampus was ipsilateral to the mesial temporal sclerosis seen on magnetic resonance imaging (MRI) and visually evident in the BP ND maps and regional TACs (Fig. 4, A to D) . The unilateral (Fig. 4E) . Regional asymmetry indices factoring in contralateral versus ipsilateral SV2A density were much higher in the hippocampus and amygdala of epilepsy patients than bilateral asymmetry in healthy subjects (Fig. 4E) . In two epilepsy patients, in addition to hippocampal synapse loss, there was asymmetry in the amygdala, consistent with previous reports that damage in the amygdala is present in a significant subpopulation of TLE patients (25) .
DISCUSSION
The number of synapses in the brain changes over the course of a lifetime, and synaptogenesis, synaptic pruning, and synaptic degeneration are key physiologic and pathologic processes regulating synaptic density (26) . Evaluation of synaptic density in humans has been limited to examination of brain tissue obtained from surgery or autopsy. However, quantification of synaptic densities in the living human brain over time is essential to our understanding, diagnosis, and treatment of brain disorders associated with synaptic pathology. Here, we presented a noninvasive method for PET imaging and quantification of synaptic density throughout the brain using the radioligand [ 11 C]UCB-J for the target SV2A-a synaptic vesicles marker that, in one baboon brain, was shown to localize with the accepted marker SYN. In humans, [ 11 C]UCB-J bound to SV2A in the brain and revealed unilateral synaptic loss in TLE patients. Thus, SV2A-PET imaging is a promising approach for quantifying synaptic density in the living human brain.
The restricted cellular localization of vesicles in synaptic boutons, their ubiquitous distribution in the brain, and high phylogenetic conservation across vertebrate nervous systems have made synaptic vesicle proteins the prime markers of synaptic density (27) (28) (29) (30) . SYN is the most abundant synaptic vesicle protein (31) and is a widely used marker of synaptic density (32, 33) , because it was one of the first characterized (29, 34) and cloned (35) vesicle membrane proteins. In the baboon case study, we demonstrated that the cellular and regional distributions of SV2A and SYN were highly correlated, suggesting that SV2A is a valid alternative synaptic density marker. Although SYN is the most polydispersed vesicle protein, possibly reflecting its variability among the vesicles of different neurotransmitter classes, SV2A is the most monodispersed synaptic vesicle protein (36) . Consequently, SV2A may provide a more accurate measure of synaptic density owing to its greater uniformity in vesicles. The relevance of SV2A as a synaptic marker was recently exemplified in a study in which the FYN tyrosine kinase inhibitor AZD0530 rescued both memory and synapse (SV2A) loss in a mouse model of Alzheimer's disease (37) .
Unlike other human imaging technologies, such as MRI, PET imaging is quantitative and provides outcome measures directly related to protein concentrations that can be cross-validated in animals or postmortem tissues. For example, V T , one PET-derived outcome measure, is proportional to the ratio of protein density (B max ) and binding affinity (K d ) (38) . No detailed regional densities of SV2A were available in the literature. However, in vitro SV2A densities were determined and found to correlate well with the in vivo PET V T values. Mean cortical B max values in baboon were 18 pmol/mg protein, somewhat higher than the values of 3 to 12 pmol/mg protein in rats (39, 40) and 3 to 4 pmol/mg protein in humans, but these differences are likely due to methodological dissimilarities in radioligand, isotope, incubation conditions, or tissue type, for instance. The estimated K d for SV2A binding by UCB-J was similar to previously reported inhibition constant (K i ) values in human tissue (6 to 7 nM), further validating our results (18) .
Saturation studies with PET can also provide estimates of in vivo B max and K d values (41) . We recently determined the in vivo K d value as 3.4 nM and cortical B max values in the range of 300 to 400 nM with [ 11 C]UCB-J in rhesus monkeys (16) , which corresponded well with the current in vitro results in baboon tissues. Thus, the SV2A density in the temporal cortex is estimated to be 5.5 × 10 17 SV2A molecules per liter of brain tissue. Assuming a density of 7.2 × 10 14 synapses per liter of brain tissue, as reported for the female human brain (42) , and two to five SV2A copies per vesicle (31, 36) , it can be estimated that there are 154 to 385 vesicles per synapse. This number is very similar to the previously reported 200 to 350 vesicles per active zone in rat cultured hippocampal preparations, Drosophila neuromuscular junctions, or rat calyx of Held terminals, although other species have higher numbers of vesicles (43) .
In patients with medically refractory TLE and concomitant mesial temporal sclerosis, in which unilateral loss of neurons is well established (5), we found~52% asymmetry in the hippocampus owing to decreased binding of [ The current study has several limitations. The overall sample size was small; PET studies were performed in 13 subjects, and tissue experiments were performed using only one baboon. Also, it could not be concluded that the centrum semiovale is a suitable reference region for [ 11 C]UCB-J quantification. A reference tissue devoid of specific binding can be used as a substitute for arterial blood sampling. In our tissue measurements, we found that the centrum semiovale contained none or negligible SV2A (at least 45-fold lower than cortical regions). However, PET studies with levetiracetam suggested a small amount of displaceable [ 11 C] UCB-J binding in centrum semiovale. These preliminary results did not include correction for the partial volume effect (45) , which causes spill-in of radioactivity from gray matter to white matter. Centrum semiovale therefore remains a promising reference region, and follow-up studies and analyses, including blocking studies in humans with other SV2A ligands, such as brivaracetam, will be required to validate the absence of SV2A-specific [ 11 C]UCB-J binding in this region. To facilitate that translation of synaptic density imaging with SV2A-PET, it is important to review a number of methodological considerations. Evaluation of the TACs suggests that the outcome measure V T can be reliably estimated using only a 60-min acquisition, which would improve patient comfort. Alternatively, using constant infusion can provide a very short imaging period during equilibrium. Notably, [ 11 C]UCB-J is radiolabeled with carbon-11, with a short half-life (t 1/2 ) of 20 min. However, diagnostic PET radioligands are typically labeled with fluorine-18 (t 1/2 = 110 min) to allow for distribution from production facilities to hospitals. Fortuitously, UCB-J contains three fluorine atoms and radiosynthesis of [ 18 F]UCB-J may thus be possible. PET imaging of SV2A now provides the unique opportunity to evaluate synaptic density in the living human brain. Our in vitro and in vivo data support the hypothesis that SV2A-PET imaging can be used as a minimally invasive, quantitative marker of synaptic density. The radioligand [ 11 C]UCB-J has exceptional PET imaging qualities for SV2A in the human brain. We demonstrate feasibility in epilepsy, but the application of SV2A-PET imaging as a synaptic marker may be particularly relevant to Alzheimer's disease, in which the pathology is characterized by accumulation of misfolded proteins (plaques composed of amyloid b, and Tau-containing neurofibrillary tangles) and synaptic loss (46) .
MATERIALS AND METHODS

Study design
The overall objective was a proof-of-concept study that SV2A-PET imaging could be a method for in vivo measurement of synaptic density. The size of the healthy control population (n = 10) was consistent with previous novel radioligand evaluation studies (47) (48) (49) and was chosen to demonstrate the imaging characteristics of the tracer, including kinetic analyses and determination of population values for the study end points (K d , V T , and BP ND ). The epilepsy patient population was chosen to demonstrate the presence of a large asymmetry in the temporal lobe. The number of epilepsy subjects was based on the small variability in the bilateral asymmetry index observed in the PET studies in healthy control subjects, and the large reduction in synaptic density in resected tissue from epilepsy subjects (2) (3) (4) (5) . All outliers were included in the analysis, and no data were excluded. No experimental groups were included in the study, and no randomization was required. The authors were not blinded to the results. We performed a terminal study in one baboon to directly compare in vivo/in vitro results of tracer binding to synaptic vesicles and localization in different brain regions; the selection of n = 1 was based on a conservative approach to terminal primate studies.
PET imaging and brain tissue measurements in a baboon
Experiments were conducted in one olive baboon (P. anubis) according to a protocol approved by the Yale University Institutional Animal Care and Use Committee, as described in Supplementary Methods.
Human subjects
Ten healthy subjects (seven males and three females; 36 ± 10 years of age) and three epilepsy subjects (three males; 52 ± 6 years of age) were included in the study. All epilepsy patients had medically refractory mesial TLE with hippocampal sclerosis and were undergoing presurgical evaluation. None of the epilepsy patients had received levetiracetam. The studies were performed under a protocol approved by the Yale University Human Investigation Committee and the Yale New Haven Hospital Radiation Safety Committee, and in accordance with the U.S. federal policy for the protection of human research subjects contained in Title 45 Part 46 of the Code of Federal Regulations (45 CFR 46) . Written informed consent was obtained from all subjects. As part of the subject evaluation, MR images were acquired on all subjects to eliminate subjects with structural brain abnormalities and for registration of PET images. MRI was performed on a 3-T whole-body scanner (Trio, Siemens Medical Solutions) with a circularly polarized head coil. The dimension and pixel size of MR images were 256 × 256 × 176 and 0.98 × 0.98 × 1.0 mm 3 , respectively.
PET measurements in human subjects In five other control subjects (subjects 6 to 10), bolus plus infusion studies were performed, where the bolus was followed by a constant infusion to the end of the PET acquisition (50) . In the bolus plus constant infusion studies, the applied K bol value was 150 min, based on simulations using the regional TACs from the five healthy control subjects evaluated with PET after bolus injection of [ 11 C]UCB-J. Baseline measurements were performed in three subjects (subjects 6 to 8). In subject 8, a second PET displacement measurement with levetiracetam was performed on the same day. Two other subjects (subjects 9 and 10) only underwent a PET measurement with levetiracetam displacement. In the displacement PET measurement, 1500 mg of the anticonvulsant levetiracetam was intravenously infused over 5 min starting 60 min after the start of The dynamic emission data were reconstructed into 33 frames (6 × 0.5, 3 × 1, 2 × 2, and 22 × 5 min) with corrections for attenuation, normalization, scatter, randoms, and dead time using the MOLAR algorithm (51) . Event-by-event motion correction (52) was included in the reconstruction on the basis of motion detection with a Polaris Vicra optical tracking system (NDI Systems) using reflectors mounted on a swim cap worn by the subject.
Arterial input functions
Each subject underwent catheterization of the radial artery for blood sampling. Samples were drawn every 10 s for the first 90 s and at 1.75, 2, 2.25, 2.5, 2.75, 3, 4, 5, 6, 8, 10, 15, 20, 25, 30, 45, 60, 75, 90, 105 , and 120 min after [ 
Image registration and definition of regions of interest
For each subject, the hardware motion-corrected dynamic PET data were coregistered to an early summed PET image (0 to 10 min after [ 11 C]UCB-J injection) using a six-parameter mutual information algorithm (FLIRT of FSL) to eliminate any residual motion. The summed PET image was coregistered to the subject's individual T1-weighted 3-T MR image (six-parameter rigid registration), which was subsequently coregistered to the automated anatomical labeling (AAL) template in the Montreal Neurological Institute (MNI) space using nonlinear transformation (BioImage Suite) (53) . Regions of interest were taken from the AAL template for SPM2 in MNI space. Using the inverse combined transformations from template to PET space, we generated regional TACs for the amygdala, caudate nucleus, centrum semiovale, cerebellum, frontal cortex, fusiform, hippocampus, occipital cortex, parietal cortex, putamen, temporal cortex, and thalamus. Values are expressed in SUV (dimensionless) equal to the regional activity concentration (Bq/ml) normalized by the ratio of injected dose (kBq) to subject weight (kg).
Quantitative analysis of [
11 C]UCB-J binding Regional TACs were analyzed with kinetic models using the arterial plasma TAC as input function. The regional distribution volumes (V T ) (38) were calculated using the 1T compartment model as K 1 /k 2 . For bolus plus constant infusion studies, V T was calculated as the ratio of tissue activity (from PET) to that in metabolite-corrected plasma. On the basis of the Western blot, homogenate binding, and confocal microscopy results, the centrum semiovale was used as a reference region for determination of nondisplaceable binding and BP ND values. Regional BP ND values were calculated as V T,region /V T,centrum_semiovale − 1.
Parametric BP ND maps were generated using the simplified reference tissue model 2 (24) References (54) (55) (56) (57) 
